Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott A Foster

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Antiviral Research|April 11, 2017
Efficacy of delayed brincidofovir treatment against a lethal rabbitpox virus challenge in New Zealand White rabbitsIrma M Grossi, Scott A Foster, Melicia R Gainey, et al.
Bioorganic & Medicinal Chemistry Letters|February 17, 2009
1,3,4-Oxadiazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 2: SAR of the C5 positionBrian A Johns, Jason G Weatherhead, Scott H Allen, et al.
Bioorganic & Medicinal Chemistry Letters|February 17, 2009
The use of oxadiazole and triazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 1: Establishing the pharmacophoreBrian A Johns, Jason G Weatherhead, Scott H Allen, et al.
Protein Expression and Purification|February 6, 2007
Remedial strategies in structural proteomics: expression, purification, and crystallization of the Vav1/Rac1 complexAlexei Brooun, Scott A Foster, Jill E Chrencik, et al.
Cell Reports|June 5, 2024
Accelerated drug-resistant variant discovery with an enhanced, scalable mutagenic base editor platformKristel M Dorighi, Anqi Zhu, Jean-Philippe Fortin, et al.
Biorxiv : the Preprint Server for Biology|August 16, 2024
Computational modeling of drug response identifies mutant-specific constraints for dosing panRAF and MEK inhibitors in melanomaAndrew Goetz, Frances Shanahan, Logan Brooks, et al.
Cancers|August 29, 2024
Computational Modeling of Drug Response Identifies Mutant-Specific Constraints for Dosing panRAF and MEK Inhibitors in MelanomaAndrew Goetz, Frances Shanahan, Logan Brooks, et al.
Bioorganic & Medicinal Chemistry Letters|December 19, 2012
Naphthyridinone (NTD) integrase inhibitors: N1 protio and methyl combination substituent effects with C3 amide groupsBrian A Johns, Takashi Kawasuji, Jason G Weatherhead, et al.
Bioorganic & Medicinal Chemistry Letters|June 9, 2014
Naphthyridinone (NTD) integrase inhibitors 4. Investigating N1 acetamide substituent effects with C3 amide groupsBrian A Johns, Takashi Kawasuji, Jason G Weatherhead, et al.
Journal of Virology|May 22, 2009
Pharmacovirological impact of an integrase inhibitor on human immunodeficiency virus type 1 cDNA species in vivoChristine Goffinet, Ina Allespach, Lena Oberbremer, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Antiviral Research|April 11, 2017
Efficacy of delayed brincidofovir treatment against a lethal rabbitpox virus challenge in New Zealand White rabbitsIrma M Grossi, Scott A Foster, Melicia R Gainey, et al.
Bioorganic & Medicinal Chemistry Letters|February 17, 2009
1,3,4-Oxadiazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 2: SAR of the C5 positionBrian A Johns, Jason G Weatherhead, Scott H Allen, et al.
Bioorganic & Medicinal Chemistry Letters|February 17, 2009
The use of oxadiazole and triazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 1: Establishing the pharmacophoreBrian A Johns, Jason G Weatherhead, Scott H Allen, et al.
Protein Expression and Purification|February 6, 2007
Remedial strategies in structural proteomics: expression, purification, and crystallization of the Vav1/Rac1 complexAlexei Brooun, Scott A Foster, Jill E Chrencik, et al.
Cell Reports|June 5, 2024
Accelerated drug-resistant variant discovery with an enhanced, scalable mutagenic base editor platformKristel M Dorighi, Anqi Zhu, Jean-Philippe Fortin, et al.
Biorxiv : the Preprint Server for Biology|August 16, 2024
Computational modeling of drug response identifies mutant-specific constraints for dosing panRAF and MEK inhibitors in melanomaAndrew Goetz, Frances Shanahan, Logan Brooks, et al.
Cancers|August 29, 2024
Computational Modeling of Drug Response Identifies Mutant-Specific Constraints for Dosing panRAF and MEK Inhibitors in MelanomaAndrew Goetz, Frances Shanahan, Logan Brooks, et al.
Bioorganic & Medicinal Chemistry Letters|December 19, 2012
Naphthyridinone (NTD) integrase inhibitors: N1 protio and methyl combination substituent effects with C3 amide groupsBrian A Johns, Takashi Kawasuji, Jason G Weatherhead, et al.
Bioorganic & Medicinal Chemistry Letters|June 9, 2014
Naphthyridinone (NTD) integrase inhibitors 4. Investigating N1 acetamide substituent effects with C3 amide groupsBrian A Johns, Takashi Kawasuji, Jason G Weatherhead, et al.
Journal of Virology|May 22, 2009
Pharmacovirological impact of an integrase inhibitor on human immunodeficiency virus type 1 cDNA species in vivoChristine Goffinet, Ina Allespach, Lena Oberbremer, et al.
Pageof 4